Tasci, E. S. Et Al. 2024. Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer. BMC CANCER , vol.24, no.1 .

Tasci, E. S., Oyan, B., Soenmez, O., Mutlu, A. U., Atci, M. M., Sakin, A., ... Oener, I.(2024). Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer. BMC CANCER , vol.24, no.1.

Tasci, Elif Et Al. "Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer," BMC CANCER , vol.24, no.1, 2024

Tasci, Elif S. Et Al. "Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer." BMC CANCER , vol.24, no.1, 2024

Tasci, E. S. Et Al. (2024) . "Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer." BMC CANCER , vol.24, no.1.

@article{article, author={Elif Senocak Tasci Et Al. }, title={Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer}, journal={BMC CANCER}, year=2024}